Clinical trials: CNS Tumor, Adult
CNS 2a, CNS 2b
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
This phase I trial studies the side effects and best dose of wee1 kinase inhibitor AZD1775 when given together with fludarabine, cytarabine, and filgrastim (FLAG) combination chemotherapy in treating children, adolescents and…
- Conditions
- CNS 2a, CNS 2b, CNS 2c, CNS1
- Trial name
- NCT02791919
- Testing
- Cytarabine, Filgrastim, Fludarabine Phosphate
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Imatinib Mesylate in Treating Patients With Gliomas
RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and slow the growth of the tumor. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have gliomas.
- Trial name
- NCT00039364
- Testing
- imatinib mesylate
- Where
- 10 sites in Austria, Belgium and 5 more
- Volunteers
- 112 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
RATIONALE: Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide.
- Trial name
- NCT01026493
- Testing
- temozolomide 60 mg x 21 days, temozolomide 75 mg x 21 days, ABT-888 20 mg x 21 days
- Where
- 17 sites in United States
- Volunteers
- 257 people
- Sponsor
- Radiation Therapy Oncology Group
Brain Tumors, Osteoporosis
Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
RATIONALE: Zoledronate may prevent bone loss in patients with primary malignant glioma. PURPOSE: This phase II trial is studying how well zoledronate works in preventing osteoporosis in patients with primary malignant glioma.
- Conditions
- Brain Tumors, Osteoporosis, Central Nervous System(CNS)Malignancies
- Trial name
- NCT00301873
- Testing
- IV Zometa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin, ifosfamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma
- Trial name
- NCT00470366
- Testing
- pegfilgrastim, cisplatin, ifosfamide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adult Immunoblastic Lymphoma, Central Nervous System Non-Hodgkin Lymphoma
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
This research study is collecting and storing tissue samples from patients with rare or cutaneous non-Hodgkin lymphoma. Collecting and storing samples of tissue from patients with cancer to test in the laboratory may help the…
- Conditions
- Adult Immunoblastic Lymphoma, Central Nervous System Non-Hodgkin Lymphoma, Childhood Immunoblastic Lymphoma, Grade 1 Follicular Lymphoma
- Trial name
- NCT01000753
- Testing
- Cytology Specimen Collection Procedure
- Where
- 130 sites in United States, Australia and 2 more
- Volunteers
- 174 people
- Sponsor
- Children's Oncology Group
Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor
A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT
This trial is evaluating the anti-tumor activity and side effects of panobinostat in treating patients with osteosarcoma, malignant rhabdoid tumor/atypical teratoid rhabdoid tumor (MRT/ATRT), and neuroblastoma.
- Conditions
- Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor, Malignant Rhabdoid Tumor, Recurrent Brain Tumor, Childhood
- Trial name
- NORTH (NCT04897880)
- Testing
- Panobinostat
- Where
- 11 sites in United States, Australia and 1 more
- Volunteers
- 25 people
- Sponsor
- Australian & New Zealand Children's Haematology/Oncology Group
Brain Metastases, Adult, Stereotactic Radiotherapy
a Feasibility Study of iHD-SRT for BM
Brain metastasis is the most challenging disease in the field of tumor treatment, with a median overall survival of only 1-2 months for untreated patients.
- Trial name
- NCT06231186
- Testing
- iHD-SRT
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Ruijin Hospital
Brain and Central Nervous System Tumors
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
RATIONALE: Radioactive drugs such as phosphorus 32 may be able to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of phosphorus 32 in treating patients with glioblastoma multiforme.
- Trial name
- NCT00004129
- Testing
- brachytherapy, phosphorus P32
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Center for Molecular Medicine
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Brain and Central Nervous System Tumors
Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow or peripheral stem cell transplantation may be able to replace immune cells that were destroyed…
- Trial name
- NCT00002619
- Testing
- filgrastim, carboplatin, thiotepa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- NYU Langone Health
Gastric Cancer, Head and Neck Cancer
Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer
RATIONALE: The Epstein-Barr virus can cause cancer and lymphoproliferative disorders. Valganciclovir is an antiviral drug that acts against the Epstein-Barr virus.
- Conditions
- Gastric Cancer, Head and Neck Cancer, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00387530
- Testing
- oral sodium phenylbutyrate, valganciclovir, polymerase chain reaction
- Where
- United States
- Sponsor
- University of California, San Diego
Chronic Myeloproliferative Disorders, Leukemia
Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003082
- Testing
- monoclonal antibody A27.15, monoclonal antibody E2.3
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Arizona
Drug/Agent Toxicity by Tissue/Organ, Lymphoma
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
Phase I trial to study the effectiveness of irinotecan plus cyclosporine and phenobarbital in treating patients who have solid tumors or lymphoma that is refractory to standard therapy.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Neutropenia, Small Intestine Cancer
- Trial name
- NCT00002759
- Testing
- cyclosporine, irinotecan hydrochloride, phenobarbital
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Brain Neoplasms, Adult, Malignant
Hippocampal-Avoiding Whole Brain Irradiation With Simultaneous Integrated Boost for Treatment of Brain Metastases
The investigators hypothesize that avoidance of the hippocampal region with WBRT (Whole-Brain Radiotherapy ) may delay or reduce the onset, frequency, and/or severity of NCF (neurocognitive function) decline, as measured with…
- Trial name
- NCT01414738
- Testing
- Radiotherapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Texas Southwestern Medical Center
Tumors
Proton Radiotherapy for Recurrent Tumors
The purpose of this study is to determine the feasibility of using proton radiotherapy for reirradiation of recurrent malignancies.
- Trial name
- NCT01126476
- Testing
- Proton Radiotherapy
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Brain and Central Nervous System Tumors
Vaccine Therapy in Treating Patients With Malignant Glioma
RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00068510
- Testing
- therapeutic autologous dendritic cells
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy, such as gossypol and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00390403
- Testing
- R-(-)-gossypol acetic acid, temozolomide, gene expression analysis
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain and Central Nervous System Tumors
Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
RATIONALE: Erlotinib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have recurrent or…
- Trial name
- NCT00054496
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- The Cleveland Clinic
Brain and Central Nervous System Tumors
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI), (done before, during, and after treatment) may help doctors predict a patient's response to treatment…
- Trial name
- NCT00274755
- Testing
- chemotherapy, conventional surgery, magnetic resonance imaging
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- University of California, San Francisco